ホーム › 非小細胞肺癌 › カリフォルニア州 › Mountain View
Mountain View、CAにおける非小細胞肺癌の臨床試験
Mountain Viewとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する21件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
被験者募集中第1/2相
- Stanford Cancer Institute (Melanoma/NSCLC), Stanford · 5マイル先
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- Palo Alto Medical Foundation-Camino Division, Mountain View
- Palo Alto Medical Foundation Health Care, Palo Alto · 5マイル先
- Stanford Cancer Institute Palo Alto, Palo Alto · 5マイル先
Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC
被験者募集中第3相
- Stanford University, Stanford · 5マイル先
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
被験者募集中第2相
- Stanford Cancer Institute, Stanford · 5マイル先
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
被験者募集中観察研究
- Stanford University, Palo Alto · 5マイル先
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
被験者募集中第2相
- Stanford Cancer Institute, Stanford · 5マイル先
- Stanford Hospital and Clinics, Stanford · 5マイル先
- Stanford Hospital Investigational Drug Services, Stanford · 5マイル先
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
被験者募集中第3相
- Stanford Cancer Center, Palo Alto · 5マイル先
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
被験者募集中第1/2相
- Stanford Cancer Institute, Stanford · 5マイル先
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
被験者募集中第1/2相
- Stanford University Medical Center - Neurology, Stanford · 5マイル先
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
被験者募集中第3相
- Palo Alto Medical Foundation Research Center, Palo Alto · 5マイル先
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
被験者募集中第1/2相
- Stanford Cancer Institute, Stanford · 5マイル先
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
被験者募集中第1/2相
- Stanford University Medical Center, Stanford · 5マイル先
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
被験者募集中第1相
- Stanford University Medical Center, Palo Alto · 5マイル先
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
被験者募集中第1相
- Stanford University, Palo Alto · 5マイル先
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
被験者募集中第1/2相
- Stanford University - Stanford Cancer Institute, Stanford · 5マイル先
A Study of LY4175408 in Participants With Advanced Cancer
被験者募集中第1相
- Stanford Medicine Cancer Center, Stanford · 5マイル先
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
被験者募集中第1/2相
- Stanford University, Stanford · 5マイル先
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
被験者募集中第1/2相
- Stanford Women's Cancer Center, Palo Alto · 5マイル先
Engagement of Veterans With Lung Cancer
被験者募集中
- Veterans Affairs Palo Alto Health Care System (VAPAHCS), Palo Alto · 5マイル先
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Stanford · 5マイル先
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
被験者募集中第1相
- Stanford University, Stanford · 5マイル先
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Mountain Viewにおける他の研究
- がん（全種類）40件の研究
- 乳がん26件の研究
- 転移性癌25件の研究
- 急性骨髄性白血病19件の研究
- 卵巣がん19件の研究
- 自閉スペクトラム症17件の研究
- 肺がん17件の研究
- 前立腺がん15件の研究
- 心不全15件の研究
- 自閉症13件の研究
- 急性リンパ性白血病13件の研究
- 大腸癌13件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。